RCKT
Price
$5.56
Change
-$0.74 (-11.75%)
Updated
Apr 3 closing price
Capitalization
591.79M
38 days until earnings call
YMAB
Price
$4.66
Change
-$0.14 (-2.92%)
Updated
Apr 3 closing price
Capitalization
210.94M
38 days until earnings call
Ad is loading...

RCKT vs YMAB

Header iconRCKT vs YMAB Comparison
Open Charts RCKT vs YMABBanner chart's image
Rocket Pharmaceuticals
Price$5.56
Change-$0.74 (-11.75%)
Volume$4.4M
Capitalization591.79M
Y-mAbs Therapeutics
Price$4.66
Change-$0.14 (-2.92%)
Volume$822.66K
Capitalization210.94M
RCKT vs YMAB Comparison Chart
Loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RCKT vs. YMAB commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RCKT is a Hold and YMAB is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (RCKT: $5.56 vs. YMAB: $4.66)
Brand notoriety: RCKT and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RCKT: 245% vs. YMAB: 192%
Market capitalization -- RCKT: $591.79M vs. YMAB: $210.94M
RCKT [@Biotechnology] is valued at $591.79M. YMAB’s [@Biotechnology] market capitalization is $210.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RCKT’s FA Score shows that 1 FA rating(s) are green whileYMAB’s FA Score has 0 green FA rating(s).

  • RCKT’s FA Score: 1 green, 4 red.
  • YMAB’s FA Score: 0 green, 5 red.
According to our system of comparison, both RCKT and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RCKT’s TA Score shows that 4 TA indicator(s) are bullish while YMAB’s TA Score has 5 bullish TA indicator(s).

  • RCKT’s TA Score: 4 bullish, 4 bearish.
  • YMAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, YMAB is a better buy in the short-term than RCKT.

Price Growth

RCKT (@Biotechnology) experienced а -29.44% price change this week, while YMAB (@Biotechnology) price change was -6.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

RCKT is expected to report earnings on May 12, 2025.

YMAB is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($592M) has a higher market cap than YMAB($211M). YMAB YTD gains are higher at: -40.485 vs. RCKT (-55.768). YMAB has higher annual earnings (EBITDA): -30.67M vs. RCKT (-247.48M). RCKT has more cash in the bank: 372M vs. YMAB (67.2M). YMAB has less debt than RCKT: YMAB (820K) vs RCKT (25.5M). YMAB has higher revenues than RCKT: YMAB (87.7M) vs RCKT (0).
RCKTYMABRCKT / YMAB
Capitalization592M211M281%
EBITDA-247.48M-30.67M807%
Gain YTD-55.768-40.485138%
P/E RatioN/AN/A-
Revenue087.7M-
Total Cash372M67.2M554%
Total Debt25.5M820K3,110%
FUNDAMENTALS RATINGS
RCKT vs YMAB: Fundamental Ratings
RCKT
YMAB
OUTLOOK RATING
1..100
589
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
39
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
9694
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (28) in the Biotechnology industry is in the same range as YMAB (39) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to YMAB’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to YMAB’s over the last 12 months.

YMAB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as RCKT (97) in the Biotechnology industry. This means that YMAB’s stock grew similarly to RCKT’s over the last 12 months.

YMAB's Price Growth Rating (94) in the Pharmaceuticals Major industry is in the same range as RCKT (96) in the Biotechnology industry. This means that YMAB’s stock grew similarly to RCKT’s over the last 12 months.

YMAB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RCKT (100) in the Biotechnology industry. This means that YMAB’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RCKTYMAB
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VENAX65.29N/A
N/A
Vanguard Energy Index Admiral
DLRHX23.02N/A
N/A
Macquarie Healthcare R
OSCCX19.09N/A
N/A
Invesco Main Street Small Cap C
GEORX5.72N/A
N/A
Pear Tree Essex Environmental Opps R6
BKRDX7.93-0.20
-2.46%
iShares Developed Real Estate Idx K